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Prenatal Alcohol exposure (PAE), like other pregnancy complications, can result 
in placental insufficiency and fetal growth restriction, though the linking causal 
mechanisms are unclear. We previously identified 11 gestationally-elevated maternal 
circulating miRNAs that predicted infant growth deficits following PAE. Here, we 
investigated whether these HEamiRNAs contribute to the pathology of PAE, by inhibiting 
trophoblast epithelial-mesenchymal transition (EMT), a pathway critical for placental 
development. We now report for the first time, that PAE inhibits expression of placental 
pro-EMT pathway members in both rodents and primates, and that HEamiRNAs 
collectively, but not individually, mediate placental EMT inhibition. HEamiRNAs 
collectively, but not individually, also inhibited cell proliferation and the EMT pathway 
in cultured trophoblasts, while inducing cell stress, and following trophoblast 
syncytialization, aberrant endocrine maturation. Moreover, a single intra-vascular 
administration of the pooled murine-expressed HEamiRNAs, to pregnant mice, decreased 
placental and fetal growth, reduced placentally directed blood flow, and inhibited 
expression of pro-EMT transcripts in placenta. Our data suggests that HEamiRNAs 
collectively interfere with placental development, contributing to the pathology of PAE, 
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Alcohol use during pregnancy remains prevalent despite published prevention 
guidelines (1). A recent meta-analysis determined the global prevalence of alcohol use 
during pregnancy at 9.8% (2). Within the United States, a 2013 study found 18% of 
women reported alcohol consumption during pregnancy, and 6.6% engaged in binge-
drinking episodes, which are particularly damaging to fetal development (3). In the state 
of Texas, we recently reported an average state-wide third-trimester rate of alcohol 
exposure of 8.4%, with rates as high as 17.7% in some localities (4). These data 
collectively suggest that prenatal alcohol exposure (PAE) is common. 
PAE harms the developing embryo and fetus and can result in a constellation of 
adverse infant outcomes, including craniofacial dysmorphologies, growth retardation, 
and neurobehavioral abnormalities, collectively termed Fetal Alcohol Spectrum 
Disorders (FASDs) (5). Estimates for the prevalence of FASDs range from 2-5% of the 
school age population in the US and Western Europe (6) to 13.6-20.9% in South Africa 
(7). Estimates for the global prevalence of fetal alcohol syndrome (FAS), the most 
severe end of the FASD continuum, characterized by cranio-facial dysmorphologies,  
growth restriction, and CNS abnormalities, range from 0.15 to 0.3% (8, 9), but are much 
higher in specific populations, for example, as high as 5.9-9.1% in the Cape Coloured 
(mixed ancestry) community in South Africa (7).  
Given the lifelong debility and economic burden associated with FASDs (10), 
 
* Part of this chapter is reprinted with permission from “Maternal circulating miRNAs that predict infant 
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there is an urgent need to develop sensitive and specific methodologies to identify 
affected children early in development, as well as develop interventions which can 
mitigate the effects of PAE on the developing fetus. In 2016, we reported that elevated 
levels of 11 distinct microRNAs (miRNAs) in 2nd and 3rd trimester maternal circulation 
distinguished infants who were affected by in-utero alcohol exposure (Heavily Exposed 
Affected: HEa) from those who were apparently unaffected at birth by PAE (Heavily 
Exposed Unaffected: HEua), or those who were unexposed (UE) (11) . We predicted that 
these HEamiRNAs (MIMAT0004569 [hsa-miR-222-5p], MIMAT0004561 [hsa-miR-187-
5p], MIMAT0000687 [hsa-mir-299-3p], MIMAT0004765 [hsa-miR-491-3p], 
MIMAT0004948 [hsa-miR-885-3p], MIMAT0002842 [hsa-miR-518f-3p], 
MIMAT0004957 [hsa-miR-760], MIMAT0003880 [hsa-miR-671-5p], MIMAT0001541 
[hsa-miR-449a], MIMAT0000265 [hsa-miR-204-5p], MIMAT0002869 [has-miR-519a-
3p]) in addition to being biomarkers of infant outcome following PAE, influence 
signaling pathways crucial for early development, particularly the epithelial-
mesenchymal transition (EMT) pathway (11).  
Placental development involves maturation of the cytotrophoblasts at the tip of 
anchoring villi into invasive extravillous trophoblasts, as well as fusion of 
cytotrophoblasts into multinucleate, hormone-producing syncytiotrophoblasts (12). 
Maturation into extravillous trophoblasts, which invade the maternal decidua and 
remodel the uterine spiral arteries into low-resistance high-flow vessels that enable 
optimal perfusion for nutrient and waste exchange, requires cytotrophoblasts to undergo 





mesenchymal-epithelial transition pathway, has been found in conditions resulting from 
placental malfunction, primarily preeclampsia (14-19). While there have been no 
previous studies directly investigating the effects of PAE on placental EMT, a rodent 
study demonstrated that PAE, during a broad developmental window, reduced the 
number of invasive trophoblasts within the mesometrial triangle, a region of the uterine 
horn directly underlying the decidua (20). Furthermore, both human and rodent studies 
have found PAE disrupts placental morphology, and interferes with cytotrophoblast 
maturation, as with preeclampsia (21-24). Disrupted trophoblast maturation, seen in 
these conditions, is associated with aberrant expression of placental hormones, primarily 
human chorionic gonadotropin (hCG) (25-28). Our study is the first to report that PAE 
interferes with expression of core placental EMT pathway members. We also provide 
evidence that a group of circulating maternal miRNAs, HEamiRNAs, which predict 
adverse infant outcomes due to PAE, mediate some of PAE’s effects and interfere with 






2. MATERIALS AND METHODS* 
2.1 Mouse model of PAE  
C57/BL6J mice (Jackson Laboratory, Bar Harbor, ME) were housed under 
reverse 12-hour dark / 12-hour light cycle (lights off at 08:00 hours). PAE was 
performed using a previously described limited access paradigm of maternal drinking 
(118, 119). Briefly, 60-day old female mice were subjected to a ramp-up period with 
0.066% saccharin containing 0% ethanol (2 days), 5% ethanol (2 days), and finally 10% 
ethanol for 4-hours daily from 10:00–14:00 beginning 2 weeks prior to pregnancy, 
continuing through gestation (Figure 1A). Female mice offered 0.066% saccharin 
without ethanol during the same time-period throughout pregnancy served as controls. 
Tissue from the labyrinth, junctional, and decidual zone of male and female gestational 
day 14 (GD14) placentae were microdissected, snap-frozen in liquid nitrogen, and stored 
at -80ᵅC preceding RNA and protein isolation. 
2.2 Mouse model for HEamiRNA overexpression  
For systemic administration of miRNAs, previously nulliparous C57/BL6NHsd 
dams (Envigo, Houston, TX) were tail-vein-injected on GD10 with either 50 μg of 
miRNA miRVanaTM mimic negative control (Thermo Fisher, Waltham, MA, Cat No. 
4464061) or pooled HEamiRNA miRVana
TM mimics in In-vivo RNA-LANCEr II (Bioo 
Scientific, Austin, TX, 3410-01), according to manufacturer instructions. The 50 μg of 
pooled HEamiRNA mimics consisted of equimolar quantities of mmu-miR-222-5p, mmu-
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miR-187-5p, mmu-mir-299a, mmu-miR-491-3p, miR-760-3p, mmu-miR-671-3p, mmu-
miR-449a-5p, and mmu-miR-204-5p mimics. For bio-distribution studies, 50 μg of 
pooled equimolar quantities of hsa-miR-519a-3p and hsa-miR-518f-3p mimics were 
injected via tail vein. These human miRNAs were selected because no mouse homologs 
are known to exist and consequently, estimates for organ distribution of exogenous 
miRNAs in the mouse are unlikely to be contaminated by the expression of endogenous 
murine miRNAs.  GD10 is a time point near the beginning of the developmental period 
of branching morphogenesis, immediately following chorioallantoic attachment, during 
which the placenta invades the maternal endometrium (120). At GD18, pregnancies were 
terminated with subsequent quantification of fetal weight, crown-rump length, snout-
occipital distance, biparietal diameter, and placental weight. Subsequently, tissue was 
snap-frozen in liquid nitrogen, and stored at -80ᵅC preceding RNA isolation. 
2.3 Rat model of PAE  
Outbred nulliparous Sprague-Dawley rats were housed under a 12-hour light/12-
hourdark cycle. PAE in Sprague-Dawley was conducted according to our previously 
published exposure paradigm (23, 121). Briefly, dams were given a liquid diet 
containing either 0% or 12.5% ethanol (vol/vol) from 4 days prior to mating until GD4 
(Figure 1B). Dams had ad libitum access to the liquid diet 21-hours daily and consumed 
equivalent calories. Water offered during the remaining 3-hours of the day. On GD5, 
liquid diets were removed and replaced with standard laboratory chow. On GD20, 
placentas were immediately separated into the labyrinth and junctional zone, snap frozen 





2.4 Non-human primate model of PAE  
As previously described in detail (91), adult female rhesus macaques were 
trained to orally self-administer either 1.5 g/kg/d of 4% ethanol solution (equivalent to 6 
drinks/day), or an isocaloric control fluid prior to time-mated breeding. Each pregnant 
animal continued ethanol exposure until gestational day 60 (GD60, term gestation is 168 
days in the rhesus macaque) (122). Pregnancies were terminated by cesarean section 
delivery at three different time points; GD85, GD110, or GD135 (Figure 1C). The 
macaque placenta is typically bi-lobed with the umbilical cord insertion in the primary 
lobe and bridging vessels supplying the fetal side vasculature to the secondary lobe 
(Figure 4D showing gross placenta anatomy) (123) . Full thickness tissue biopsies 
(maternal decidua to fetal membranes) were taken from both the primary and secondary 
lobes of the placenta (Figure 4D showing H&E section of placenta). Samples were 







Figure 1: PAE paradigms in mouse, rat, and macaques 
A) Timeline of mouse alcohol administration 
B) Timeline of rat alcohol administration 
C) Timeline of macaque alcohol administration 
 
2.5 Characterization of fetal blood flow dynamics 
 Ultrasound imaging was conducted as previously described. Briefly, dams were 
anesthetized using isoflurane (anesthesia was initiated with 3–4% isoflurane and 
maintained with 1% isoflurane). Dams were maintained in the supine position on a 
temperature-controlled platform (with sensors for monitoring of maternal 
electrocardiogram, respiration and core body temperature, Visualsonics, Toronto, 
Canada). Prior to imaging, the abdomen was depilated (using Nair) to improve contact 
with the transducer and ultrasound gel applied. For each pregnant dam, a fetus in the 
upper left and upper right quadrant of the uterine horn were selected for repeated 
imaging on GD12, GD14, and GD18. Color and pulse wave Doppler measurements for 





ultrasound imaging machine coupled to a MS550D Microscan™ transducer with a 
center frequency of 40MHz (Visualsonics, Canada).  
2.6 Cell culture trophoblast models  
BeWO human cytotrophoblastic choriocarcinoma cells and HTR-8/SVneo 
extravillous cells were sourced from ATCC (Manassas, VA, Cat No. CCL-98 and CRL-
3271 respectively). BeWO cells were maintained in HAM’s F12 media containing 
penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% vol/vol fetal calf serum (FCS) 
at 37°C and 5% CO2. HTR8 cells were maintained in RPMI-1640 media with 5% 
vol/vol FCS, under otherwise identical conditions. Culture medium was replenished 
every 2 days and cells sub-cultured every 4-5 days.  
BeWO cells were treated with 20 µm forskolin to induce syncytialization, as 
previously described (124, 125). BeWO and HTR8 cells were also subjected to four 
separate ethanol treatment conditions: 0 mg/dL, 60 mg/dl (13 mM),120 mg/dl (26 mM) 
or 320 mg/dl (70 mM). To achieve HEamiRNA overexpression and inhibition, 
Dharmacon miRIDIANTM miRNA mimics and hairpin inhibitors [25 nM], or control 
mimic (Dharmacon, Lafeyette CO, Cat No. CN-001000-01-05) and hairpin inhibitor 
(Dharmacon, Cat No. CN-001000-01-05) [25nm], were transfected into subconfluent 
BeWO and HTR8 cells using RNAIMAX lipofection reagent (Thermo Fisher, Cat No. 
13778).  
2.7 Cell cycle analysis 
At 48-hours-post transfection, BeWO cells were pulsed with 10 μM EdU for 1-





Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay Kit (Thermo Fisher, Cat No. 
C10420), in conjunction with 7AAD (Thermo Fisher, Cat No. 00-6993-50), according to 
manufacturer instructions, using the Beckman Coulter® Gallios 2/5/3 Flow Cytometer. 
Data was analyzed using Kaluza software (Beckman Coulter, Brea, CA). 
2.8 Cell death analysis 
BeWO cell culture was harvested 48-hours post transfection media was subjected 
to lactate dehydrogenase (LDH) detection using the Pierce™ LDH Cytotoxicity Assay 
Kit (Thermo Fisher, Cat No. 88953), according to manufacturer instructions, for lytic 
cell death quantification. The Promega Caspase-Glo® 3/7 Assay Systems (Promega, 
Madison, WI, Cat No. G8091) was used to quantify apoptotic cell death 
2.9 Invasion assay 
At 24-hours post-transfection and/or ethanol exposure, HTR8 cells were serum 
starved for an additional 18-hours. Subsequently, HTR8 cells were seeded onto trans-
well permeable supports precoated with 300 µg/mL Matrigel (Corning, Corning, NY, 
Cat No. 354248). After 24-hours, cells remaining in the apical chamber were removed 
with a cotton swab. Cells that invaded into the basal chamber were incubated with 1.2 
mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 3-hours, 
and the precipitate solubilized with 10% sodium dodecyl sulfate in 0.01N hydrochloric 
acid. Absorbance intensities were read at 570 nm in a Tecan Infinite® 200 plate reader. 
2.10 Metabolic flux analysis and calcium imaging 
BeWO cells (10,000/well) were plated into Seahorse XF96 Cell Culture 





rate (OCR), a measure of mitochondrial respiration, and extracellular acidification rate 
(ECAR), a measure of glycolysis, were measured using the Seahorse XFe96 flux 
analyzer (Seahorse Bioscience, North Billerica, MA). At the time of assay, cell culture 
medium was replaced with the appropriate pre-warmed Seahorse XF Base Medium 
(Agilent Biotechnology, Santa Clara, CA, Cat No. 102353-100). OCR and ECAR 
parameters were measured using the Seahorse XFp Cell Energy Phenotype Test KitTM 
(Agilent Biotechnology, Cat No. 103275-100). Metabolic stress was induced by 
simultaneous treatment with 1μm Oligomycin and 0.125µM Carbonyl cyanide p-
[trifluoromethoxy]-phenyl-hydrazone (FCCP). 
BeWO cells were also plated onto glass coverslips in 24 well plates at a density 
of 30,000 cells/well. After exposure to ethanol and/or forskolin in culture, cells were 
prepared for calcium imaging. After replacement of culture media with external imaging 
media (154 mM NaCl, 5 mM KCl, 2 mM CaCl2, 0.5 mM MgCl2, 5 mM glucose, 10 mM 
HEPES, pH 7.4), cells were loaded for 35 minutes at 37°C with the calcium indicator 
dye fluo-4 AM (Thermo Fisher Scientific, Cat No. F14201), at a final concentration of 
5µM fluo-4 AM in 0.1% DMSO. After incubation, cells were washed to remove 
remaining extracellular fluo-4 and imaged at 40x using confocal microscopy (FV1200-
equipped BX61WI microscope, Olympus Corporation, Center Valley, PA). Time-lapse 
images were acquired at a frequency of 0.5Hz. Individual cells were manually outlined, 
and area and mean fluorescence intensity were obtained for each cell (FIJI image 
processing package)(126) . To determine the functional calcium range of each cell, at the 





external Ca2+, Frange = Fionomycin- FEGTA). Baseline fluorescence was determined by 
averaging the lowest 5 consecutive fluorescence values during the initial 5 minutes 
(Fbaseline) which was then expressed as a percentage of Frange (ΔFbaseline = (Fbaseline-
FEGTA)/Frange X100). Maximal intracellular calcium response to 100 µM ATP was 
determined by averaging the highest 3 consecutive fluorescence values during ATP 
application (FATP) and determining the amount of fluorescence as a percentage of Frange 
(ΔFATP = (FATP-FEGTA)/Frange X100). 
2.11 Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
analysis 
Total RNA was extracted from tissue, well as BeWO and HTR8 cells, using the 
miRNeasy Mini kit (Qiagen, Cat No. 217004). For miRNA qPCR assays, cDNA was 
synthesized from 200 ng of total RNA using the miRCURY LNA Universal RT cDNA 
synthesis kit (Exiqon, Cat No. 203301/Qiagen, Cat No. 339340, Germantown, MD) and 
expression was assessed using miRCURY LNA SYBR Green (Exiqon, Cat No. 
203401/Qiagen, Cat No. 339345). For mRNA qPCR assays, cDNA was synthesized 
from 500 ng of total RNA using the qScript™ cDNA Synthesis Kit (Quanta/Qiagen, Cat 
No. 95047). Gene expression analysis was performed using PerfeCTa SYBR Green 
FastMix (Quanta, Cat No. 95073) on the ViiA 7 Real-Time PCR System (Thermo Fisher 
Scientific). The data presented correspond to the mean 2-ΔΔCt after being normalized to 
the geometric mean of β-actin, HPRT1, and 18s rRNA. Expression data for miRNA was 
normalized to the geometric mean of miR-25-3p, miR-574-3p, miR-30b-5p, miR-652-





evidence of a single amplicon and the length of each amplicon was verified using 
agarose gel electrophoresis. A list of primers and their sequences is presented in Table 1. 
2.12 Western immunoblotting analysis 
Protein was extracted using 1X RIPA lysis buffer (Millipore Sigma, Burlington 
MA) supplemented with Halt protease inhibitor cocktail (Thermo Fisher Scientific). 
Tissue was homogenized using the Branson Sonifier 150. Protein concentration was 
determined using Pierce BCA protein assay kit (Thermo Fisher Scientific) and 30 μg of 
protein was loaded onto a 4-12% Bis-Tris (Invitrogen/Thermo Fisher Scientific, Cat No. 
NPO323BOX), size fractionated at 200 V for 35 minutes, and transferred to a PVDF 
membrane using the iBlot transfer system (Invitrogen/Thermo Fisher Scientific). Blots 
with protein from cultured cells were blocked with 5% nonfat dry milk in tris-buffered 
saline containing Tween®-20 (TTBS) for 1-hour and incubated overnight with primary 
antibody. The blot was then washed and incubated with an HRP-conjugated goat anti-
rabbit or anti-mouse IgG (Invitrogen) at dilution 1:1000 for 1-hour, then developed using 
PerkinElmer Western Lightning Plus Chemi ECL (PerkinElmer; Waltham, MA) and 
visualized using a CCD camera (Fluorchem Q, Alpha Innotech; San Leandro, CA). Blots 
with protein from homogenized tissue were dried overnight, rehydrated in methanol, 
stained with REVERT™ Total Protein Stain and developed with the Odyssey CLx 
Imaging System (LI-COR, Lincoln, NE). Blots were then blocked with Odyssey® 
Blocking Buffer (TBS) for 1h and incubated overnight with primary antibody. The blot 
was then washed and incubated with IRDye® 800CW secondary antibody (LI-COR, Cat 





Biotechnology, Cat No. sc-47778); Goat anti-Mouse IgG (H+L) Secondary Antibody, 
HRP (Thermo Fisher, Cat No. 62-6520); Goat anti-Rabbit IgG (H+L) Secondary 
Antibody, HRP (Thermo Fisher, Cat No. 65-6120); purified Mouse Anti-E-cadherin (BD 
Biosciences, Cat No. 610181), Rabbit anti-vimentin antibody [EPR3776] (Abcam, Cat 
No. ab 924647). Protein levels were quantified using the densitometric analysis package 
in FIJI image processing software (126). 
2.13 ELISA 
The 2nd and 3rd trimester maternal plasma samples were collected as part of a 
longitudinal cohort study conducted in two regions of Western Ukraine as part of the 
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD.org) between the 
years 2006 and 2011, as previously reported(11). Plasma, at a 1:1000 dilution, was 
subjected to hCG detection using Abcam’s intact human hCG ELISA kit (Cat no. 
ab100533) following the manufacturer’s protocol.  
2.14 Literature review 
We conducted a literature review for HEamiRNAs and their associated gestational 
pathology using the National Institute of Health’s Pubmed search interface. For each 
miRNA, the following search parameters were used:  
[miRX OR miR X OR miRNA X OR miRNAX or miRNX] AND MeSH Term 
where X represents the miRNA of interest and automatic term expansion was enabled. 
The following MeSH terms, and related search terms (in brackets), were used: Fetal 
Growth Retardation [Intrauterine Growth Retardation, IUGR Intrauterine Growth 





Birth [Preterm Birth, Preterm Birth, Preterm Infant, Premature Infant, Preterm Labor, 
Premature Labor], Spontaneous Abortion [Early Pregnancy Loss, Miscarriage, Abortion, 
Tubal Abortion, Aborted Fetus], Pre-Eclampsia [Pre Eclampsia, Preeclampsia, 
Pregnancy Toxemia, Gestational Hypertension, Maternal Hypertension], and Maternal 
Exposure [Environmental Exposure, Prenatal Exposure]. Returned articles were 
subsequently assessed for relevance. 
 
Figure 2: Bioinformatics pipeline used to analyze HEamiRNA pri-miRNA expression in tissues. 
2.15 Secondary analysis of RNA sequencing data  
Expression levels of HEamiRNAs in tissues were determined using the Human 
miRNA Expression Database and the miRmine Human miRNA expression database(66, 





used from NCBI’s sequence read archive (https://www.ncbi.nlm.nih.gov/sra). The 
accession numbers for the sequence files are: uterus (SRR1957209), thyroid 
(SRR1957207), thymus (SRR1957206), stomach (SRR1957205), spleen (SRR1957203), 
small intestine (SRR1957202), skeletal muscle (SRR1957201), salivary gland 
(SRR1957200), placenta (SRR1957197), lung (SRR1957195), liver (SRR1957193), 
kidney (SRR1957192), heart (SRR1957191), whole brain (SRR1957183), adrenal gland 
(SRR1957124), bone marrow (ERR315396), colon (ERR315484), adipose tissue 
(ERR315332), and pancreas (ERR315479). Deep sequencing analysis was conducted 
using the Galaxy version 15.07 user interface according to the bioinformatics pipeline 
outlined in Figure 2. 
2.16 Statistical analyses 
Linear regression models were used to estimate associations between infant 
growth measures and miRNA expression levels, gestational age at blood draw, the 
interaction between subject-centered miRNA expression level and gestational age at 
blood draw, and child sex. Spearman correlations between infant growth measures and 
subject-centered miRNA expression levels were also calculated. Linear regression 
models were also used to estimate the associations between gestational at birth and log-
transformed hCG levels, ethanol intake, the interaction between log-transformed hCG 
levels and ethanol intake, gestational at blood draw, and child sex. Statistical Analysis 
and graphs were generated with GraphPad Prism 6 software (GraphPad Software, Inc., 
La Jolla, CA), SPSS v24, or R version 3.3.1. Results are expressed as the mean ± SEM, 





of 1st and 3rd quartile, a median line in the center of the box, and whiskers representing 
the total range of data. The overall group effect was analyzed for significance using 1-
way MANOVA, 1-way or 2-way ANOVA with Tukey’s Honest Significance Difference 
(HSD) post-hoc testing when appropriate (i.e. following a significant group effect in 1-
way ANOVA or given a significant interaction effect between experimental conditions 
in 2-way ANOVA), to correct for a family-wise error rate. A 2-tailed Student’s t-test 
was used for planned comparisons. For experiments characterizing the individual effects 
of HEamiRNAs against the control miRNA or antagomirs, individual 2-tailed Student’s t-
test with 5% FDR correction was applied to account for multiple comparisons. All 
statistical tests, sample-sizes, and post-hoc analysis are appropriately reported in the 
results section. A value of p < 0.05 was considered statistically significant, and a value 








Figure 3: HEamiRNAs are placentally enriched and associated with gestational pathologies 
A) Venn diagram on number of HEamiRNAs reported to be associated with different gestational 
pathologies. Inset colored circles represent the corresponding sex and gestational age-adjusted growth 
parameters these miRNAs were correlated with. Of the 22 studies queried, 11 (50%) utilized unbiased 
screenings for miRNA expression. 
B) Heatmap of mature HEamiRNA expression and C) pri-HEamiRNA expression across different tissues 




* Part of this chapter is reprinted with permission from “Maternal circulating miRNAs that predict infant 
FASD outcomes influence placental maturation” by Tseng et al., 2019. Life Science Alliance, Vol. 2, © 





3.1 HEamiRNAs are implicated in placental-associated pathologies  
Outside of our report that elevated HEamiRNA levels predict infant outcomes 
following PAE, few other studies have investigated expression of these miRNAs in the 
context of PAE or other potentially toxic prenatal exposures (29-36). Given our 
prediction that HEamiRNAs interfere with signaling pathways governing fetal and 
placental development (11), we conducted a literature review of reports on HEamiRNA 
levels in gestational pathologies which, as with PAE, include aberrant placentation as an 
etiological factor (37-39). Surprisingly, placental and plasma levels of 8 out of 11 of 
these HEamiRNAs were significantly dysregulated in one or more of these gestational 
pathologies with expression of the majority of these 8 miRNAs altered in both fetal 
growth restriction and preeclampsia (Figure 3A) (33, 34, 36, 40-57), both of which are 
characterized by poor placental invasion as an etiological factor (58-64).  
3.2 HEamiRNAs explain variance in infant growth outcomes due to PAE 
Given the association of individual HEamiRNAs with gestational pathologies, we 
sought to determine if circulating HEamiRNAs levels could explain the variance in sex 
and gestational age-adjusted neonatal height, weight and head circumference in our 
Ukrainian birth cohort, which are growth measures sensitive to in utero environment 
(65). We found that 8 of the HEamiRNAs, each significantly explained between 7 to 19% 
of infant variation in these growth measures (Table 2). Furthermore, 7 of these miRNAs 
were also associated with fetal growth restriction and preeclampsia as identified by our 
literature review. Additionally, only 1 of the 3 miRNAs not previously-reported to be 





development in our dataset (Figure 3A). Interestingly, a multivariate statistical 
regression model that accounted for levels of all 11 HEamiRNAs together, explained a far 
greater proportion of infant variance, between 24-31%, in all three growth measures than 
accounting for them individually (Table 3). 
3.3 HEamiRNAs are transcribed preferentially in the placenta 
Data extracted from publicly available gene expression profiling datasets (66) 
show that HEamiRNAs as well as their unprocessed precursor transcripts, HEapri-miRNAs, 
are enriched in placenta compared to other tissues, suggesting that the placenta itself 
transcribes these miRNAs and may be a significant contributory tissue to maternal 
circulating HEamiRNAs (Figures 3B and C). Since chorionic villi are immersed in 
maternal blood, it is possible that the placenta is both a source and a target of maternal 
HEamiRNAs. Moreover, since HEamiRNAs are also associated with gestational 
pathologies caused by poor placental invasion, these HEamiRNAs may also constitute an 
intra-placental paracrine signal to coordinate the (mal)adaptive response of tissues to 
PAE. We therefore assessed in rodent and primate models, whether PAE could result in 
impaired EMT, and if HEamiRNAs could explain the effects of PAE on placental EMT-





Figure 4: HEamiRNAs mediate the effect of PAE on EMT pathway members in mouse and macaque 
placentas. 
A) Histological image of GD14 mouse placenta. Outlined in red is the labyrinth zone, blue is the 
junctional zone, black is the decidual zone. Inset is a high magnification image of the labyrinth zone.  
B) MANOVA of gene expression of core EMT pathway members in different regions of the mouse 
placenta in control and PAE mice (n=29 samples). 
C) MANCOVA of gene expression of core EMT pathway members in the mouse placental labyrinth zone 
before (Basic Model) and after accounting for the expression of HEamiRNAs (n=29 samples). 
D) Gross anatomy photograph of the primary (left) and secondary (right) lobes of a GD135 macaque 
placenta. Outlined in red is an individual cotyledon from the secondary lobe. Inset is a full thickness 
hematoxylin and eosin stained histological section of a representative cotyledon with the fetal membranes 
outlined in black, villous tissue outlined in red and maternal decidua in blue.  
E) MANCOVA of gene expression of core EMT pathway members in placental cotyledons of PAE and 
control macaques, accounting for the expression of HEamiRNAs collectively (n=23 samples). 
F) MANCOVA of gene expression of core EMT pathway members in macaque placentas after accounting 






Figure 5: PAE interferes with the EMT pathway in mouse and macaque placentas 
Expression of A) CDH1, B) VIM, C) SNAI1, D) TWIST, and E) SNAI2 in the placental labyrinth zone of 
PAE and control mice (n=5-12 samples per group). 
Densitometric quantification of E-cadherin expression in the in F) junctional, G) decidual, and H) 
labyrinth zone of PAE and control mice as well as representative blot of E-cadherin expression and total 
protein expression (right, n=5-12 samples per group). 
Expression of I) CDH1, J) VIM, K) SNAI2, and L) TWIST transcripts in PAE and Control macaque 
placental cotyledons (n=3-5 samples per group). 
Results are expressed as the mean ± SEM, LDR=Molecular Weight Ladder; ANOVA: significant main 
effect of PAE [Ɛp<0.05, ƐƐƐp<0.001], significant interaction effect (sex by PAE, [†p<0.05]). For post-hoc 
analysis, ***p<0.001 by Tukey’s HSD. 
 
3.4 HEamiRNAs moderate PAE’s effects on EMT pathway members   
EMT, in trophoblasts, is characterized by the disappearance of epithelial markers 
like E-cadherin and the appearance of the mesenchymal markers like the intermediate 





determination transcription factors, Snail1 and 2 and TWIST, as extensively described 
(13, 17, 18, 67-70). These five markers have been used extensively to assess EMT in a 
variety of model systems and therefore our studies utilized these markers to investigate 
the effects of alcohol and HEamiRNAs on trophoblast EMT. 
In the first analysis, using a murine model of PAE that mimicked moderate to 
binge-type alcohol consumption throughout early and mid-pregnancy, we fractionated 
GD14 placenta into three zones: the cytotrophoblast and syncytiotrophoblast rich 
labyrinth zone, the glycogen and spongiotrophoblast rich junctional zone, and the 
decidual zone comprising the endometrial contribution to the placenta (Figure 4A). 
Multivariate analysis of variance (MANOVA) for expression of these five core genes in 
the EMT pathway within placental trophoblasts, revealed a significant effect of ethanol 
exposure on EMT pathway member expression selectively within the labyrinth zone 
(Pillai’s trace statistic, F(5,21)=6.85, p<0.001, Figure 4B) but not within the junctional or 
decidual zones. Post-hoc univariate ANOVA indicated ethanol exposure specifically 
elevated CDH1 (F(1,25)=7.452, p=0.011), which encodes epithelial E-cadherin, whereas 
expression of the pro-mesenchymal transcription factor SNAI1 was significantly reduced 
(F(1,25)=21.022, p=0.0001). We also observed a significant interaction between fetal sex 
and PAE on expression of SNAI2 (F(1,25)=2.18, p=0.047) and a trend towards decreased 
expression of the terminal mesenchymal marker VIM (Vimentin, F(1,25)=2.749, p=0.11), 
while there was no effect on TWIST expression (Figures 5A-E). Consistent with our gene 
expression data, E-cadherin protein levels were significantly elevated in the labyrinth 





zones (Figure 5F-H). However, when we controlled for expression of the 8 mouse 
homologues of HEamiRNAs as a covariate, using multivariate analysis of covariance 
(MANCOVA), ethanol’s effect on EMT became marginally nonsignificant (Pillai’s 
trace, F(5,21)=2.713, p=0.068) (Figure 4C), suggesting that these miRNAs only partially 
mediate effects of PAE on EMT pathway members in mice.  
To determine if effects of PAE on EMT pathway members in placenta are 
broadly conserved throughout mammalian evolution, we adopted a non-human primate 
(macaque) model of moderate to binge-type alcohol consumption. Placental tissues were 
isolated from GD85, GD110, and GD 135 placenta (Figure 4D), which spans the human 
equivalent of mid-second to mid-third trimester (Figure 1C). There was a significant 
effect of ethanol exposure on expression of core EMT mRNA transcripts by MANOVA 
(Pillai’s trace statistic, F(4,9)=4.229 p=0.045, Figure 4E). Consistent with our findings in 
mouse, post-hoc univariate ANOVA indicated that in primate placenta, ethanol exposure 
significantly increased CDH1 expression (F(1,12)=4.866, p=0.048) whereas VIM 
expression was significantly reduced (F(1,12)=12.782, p=0.0004), suggesting that, as in 
the mouse, PAE also impairs EMT in the primate placenta. Interestingly, there was no 
effect on SNAI2 or TWIST expression (Figures 5I-L). As in mice, accounting for 
expression of HEamiRNAs together as a covariate abolished the significant effect of PAE 
on EMT, though to a greater degree than mice (Pillai’s trace, F(1,1)=1.605, p=0.425, 
Figure 4E). Interestingly, accounting for expression of individual HEamiRNAs did not 
explain the effects of PAE on placental EMT, suggesting that HEamiRNAs act in concert 





peri-conceptional period in rats also influenced expression of EMT core transcripts 
(Figure 1B and Figures 6A-E). 
 
Figure 6: PAE and expression of core EMT transcripts in rat placenta 
A) Expression of CDH1, B) Snai1, C) VIM, D) Snai2, and E) TWIST in the placental labyrinth zone of 
PAE and control rats.  
Results are expressed as expressed as the mean ± SEM, n=8 samples per group; ANOVA: significant main 
effect of PAE [#p<0.05]. 
 
Collectively, our data suggests PAE induced impairment of EMT in the 
trophoblastic compartment of placentae is conserved between rodents and non-human 
primates and that HEamiRNAs, particularly in primates, may moderate the effect of PAE 
on placental EMT. Consequently, subsequent studies focused on the collective role of 
HEamiRNAs, either on basal or on alcohol-influenced placental trophoblast growth, 






Figure 7: Individual HEamiRNAs do not affect EMT pathway in BeWO cytotrophoblasts 
Heatmap for expression of core members of the EMT pathway following overexpression of individual 
HEamiRNAs or a control (Ctrl) miRNA. Scale for heatmap coloration, right, depicts row-centered Z-score, 
n=10 samples per group. 
 
3.5 HEamiRNAs impair EMT pathway member expression in a model of human 
cytotrophoblasts 
To investigate whether HEamiRNAs collectively interfere with the EMT pathway, 
as suggested by our in vivo data, we measured expression of core members of the EMT 
pathway after transfecting HEamiRNA mimics and antagomirs into BeWO 
cytotrophoblasts. Cytotrophoblasts normally undergo EMT to become invasive 
trophoblasts, which we also modelled using the HTR8 human extravillous trophoblast 
cell line. We initially overexpressed each of the 11 HEamiRNAs individually, to 
determine whether any of them could alter mRNA transcripts for EMT pathway 
members. However, we did not observe any significant effects due to overexpression of 
individual miRNAs (Figure 7), consistent with our findings in the primate PAE model 





transfection of pooled HEamiRNAs into cytotrophoblasts (Figure 8A) significantly 
increased CDH1 expression (F(1,36)=30.08, p<0.0001). Interestingly, expression of the 
pro-mesenchymal transcription factors TWIST and SNAI1 were also significantly 
reduced, but only in the context of concomitant 320 mg/dL ethanol treatment, pointing to 
an interaction effect between HEamiRNAs and ethanol (F(1,36)= 5.650 and 5.146 
respectively, p=0.023 and p=0.029, Figures 8B-E). Consistent with our qPCR data, 
transfection of HEamiRNAs also significantly increased E-cadherin protein expression 
(F(1,20)=33.86, p<0.0001, Figure 8F). We were unable to detect SNAI2 transcript 









miRNAs interfere with the EMT pathway in BeWO cytotrophoblasts 
A) Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting 
cytotrophoblasts. 
Expression of B) CDH1, C) VIM, D) TWIST, and E) SNAI1 transcripts F) and densitometric quantification 
of E-cadherin protein levels in BeWO cytotrophoblasts following 
HEa
miRNAs or control miRNA 
overexpression with or without concomitant 320 mg/dL ethanol exposure. 
G) Expression of CDH1, H) VIM, I) TWIST, and J) SNAI1 transcripts K) and densitometric quantification 
of E-cadherin protein levels in BeWO cytotrophoblasts following 
HEa
miRNAs or control hairpin inhibitor 
transfection with or without concomitant 320 mg/dL ethanol exposure. Results are expressed as the mean 
± SEM, LDR=Molecular Weight Ladder, n=10 samples per group; ANOVA: significant main effect of 
HEamiRNA transfection [####p<0.0001], significant interaction effect (HEamiRNA by 320mg/dL ethanol, 
[†p<0.05, †††p<0.001]). For post-hoc analysis *p<0.05, **p<0.01 by Tukey’s HSD. 
 
Whereas transfection of HEamiRNA mimics increased CDH1 expression, 
transfection of pooled antagomirs to HEamiRNAs, significantly reduced CDH1 
expression, only in the context of 320 mg/dL ethanol co-exposure (post-hoc Tukey’s 





between ethanol exposure and HEamiRNA inhibition (F(1,36)=13.51, p=0.0008, Figure 
8G). However, expression of TWIST was also decreased in this context and there was no 
significant difference in E-cadherin protein expression relative to the control (Figure 8H-
K). Thus, our data suggest that, increasing HEamiRNA levels impairs EMT pathway 
members in cytotrophoblasts whereas inhibiting their action has a more restricted effect 
on EMT pathway members.  
 
Figure 9: HEamiRNAs subpools have different effect on the EMT pathway in BeWO  
cytotrophoblasts 
A) Venn diagram with the diamond indicating HEamiRNAs broadly implicated in gestational pathologies 
and the triangle outlining miRNAs implicated in preeclampsia and fetal growth restriction.  
Expression of B) CDH1 C) VIM D) TWIST and E) SNAI1 transcripts following control (C), [hsa-miR-222-
5p and hsa-miR-519a-3p] (GP), or [hsa-miR-885-3p, hsa-miR-518f-3p, and hsa-miR-204-5p] (PE/FGR) 
overexpression. Results are expressed as expressed as the mean ± SEM, n=5 samples per group; ANOVA: 
significant treatment effect [#p<0.05, ###p<0.001]. For post-hoc analysis, *p<0.05, **p<0.01, and 
****p<0.0001 by Dunnett’s Multiple Comparisons. 
 
We next sought to determine if more restricted subsets of HEamiRNAs could 
recapitulate the effects of HEamiRNAs collectively on EMT. Thus, we overexpressed 





growth restriction, as well as hsa-miR-885-3p, hsa-miR-518f-3p, hsa-miR-204-5p, 
which are implicated in preeclampsia, fetal growth restriction, and spontaneous abortion 
or preterm labor (Figure 9A).  In contrast to the collective action for all HEamiRNAs, 
exposure to each of these pools resulted in significant decreases in CDH1 expression 
(F(2,12)=20.12, p=0.0001). The pool including hsa-miR-885-3p, hsa-miR-518f-3p, hsa-
miR-204-5p also significantly increased Snai1 (F(2,12)=4.604, p=0.0328; Dunnett’s post-
hoc p=0.0497, Figure 9B-E). These data suggest that HEamiRNAs include sub-groups of 
miRNAs that have the potential to partly mitigate the effects of elevating the entire pool. 
However, the potential protective effects of these sub-groups are masked by the 
collective function of the entire group of HEamiRNAs. 
3.6 HEamiRNAs impair EMT member expression in a model of human extravillous 
trophoblasts 
We next investigated the effect of HEamiRNAs on EMT in HTR-8/SVneo 
extravillous trophoblast-type cells (Figure 10A). Transfecting pooled HEamiRNA mimics 
into extravillous trophoblasts significantly decreased VIM expression (F(1,36)=28.43, 
p<0.0001). Expression of pro-mesenchymal transcription factors SNAI2 was also 
reduced (F(1,36)= 64.88 respectively, p<0.0001). As with cytotrophoblasts, expression of 
SNAI1 and TWIST were reduced only with 320 mg/dL ethanol co-exposure (post-hoc 
Tukey’s HSD, p =0.027 and p<0.0001 respectively) indicating an interaction effect 
(F(1,36)=4.21 and 5.18, p=0.048 and 0.029 respectively, Figures 10B-E). Consistent with 
our qPCR data, Vimentin protein expression was also significantly reduced 





alcohol exposure on decreasing vimentin protein expression (F(1,20)=7.303, p=0.014). We 
were unable to detect expression of CDH1 transcript, or its E-cadherin protein product, 




miRNAs interfere with the EMT pathway in HTR8 extravillous trophoblasts 
A) Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting 
extravillous trophoblasts. 
Expression of B) SNAI2 C) VIM D) TWIST and E) SNAI1 transcripts F) as well as densitometric 
quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following 
HEa
miRNAs or 
control miRNA overexpression with or without concomitant 320 mg/dL ethanol exposure. 
Expression of G) SNAI2 H) VIM I) TWIST and J) SNAI1 transcripts K) as well as densitometric 
quantification of Vimentin protein levels in HTR8 extravillous trophoblasts following 
HEa
miRNA or 
control hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol exposure. 
Results are expressed as the mean ± SEM, LDR=Molecular Weight Ladder, n=10 samples per group; 
ANOVA: significant main effect of HEamiRNA transfection [##p<0.01, ####p<0.0001], significant main 
effect of 320mg/dL ethanol exposure [ƐƐp<0.01], significant interaction effect (HEamiRNA by 320mg/dL 







In contrast to HEamiRNA mimics, transfecting pooled antagomirs significantly 
increased VIM expression (F(1,35)=42.56,  p<0.0001). Likewise, there were interaction 
effects for SNAI1 and SNAI2 (F(1,35)=10.31 and 4.86, p=0.01 and p=0.034 respectively), 
whereby antagomir transfection increased expression of Snai2 in the context of 
320mg/dL ethanol co-exposure (post-hoc Tukey’s HSD, p<0.0001) and Snai1 under 
basal conditions (post-hoc Tukey’s HSD, p<0.0001)(Figures 10G-J). Despite our qPCR 
data, we did not observe significant differences in vimentin protein expression between 
treatment groups (Figure 10K). Collectively, our data indicate that increased 
trophoblastic HEamiRNA levels favors an epithelial phenotype, whereas inhibiting their 







Figure 11: Antagomirs prevent
 HEa
miRNA induced impairment of EMT  
Expression of A) CDH1 B) VIM C) TWIST and D) SNAI1 transcripts following control or 
HEa
miRNA 
hairpin inhibitor transfection followed by control or 
HEa
miRNA overexpression in BeWO cytotrophoblasts. 
Expression of E) CDH1 F) VIM G) TWIST and H) SNAI1 transcripts following control or 
HEa
miRNA 
antagomir transfection followed by control or 
HEa
miRNA overexpression in HTR8 extravillous 
trophoblasts.  
In subheadings: C denotes control miRNA mimic or hairpin whereas T denotes 
HEa
miRNA mimic or 
hairpin inhibitor. Results are expressed as expressed as the mean ± SEM, n=10 samples per group; 
ANOVA: significant treatment effect [##p<0.01, ###p<0.001, ####p<0.0001]. For post-hoc analysis, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 by Tukey’s HSD. 
 
3.7 Antagomirs prevent HEamiRNAs’ inhibition of EMT pathway members 
We next investigated if pretreating trophoblasts with pooled HEamiRNA 
antagomirs could prevent inhibition of the EMT pathway caused by transfecting 
HEamiRNA mimics. CDH1 expression in cytotrophoblasts transfected with control 
antagomir, and subsequently transfected with control mimic, was not significantly 
different from those transfected with HEamiRNA antagomirs and HEamiRNA mimics. 





antagomir and HEamiRNA mimics (post-hoc Tukey’s HSD, n=10 samples per group, 
p=0.004). Likewise, cells pre-transfected with HEamiRNA antagomirs had significantly 
higher SNAI1 and VIM expression than those pre-transfected with control antagomir and 
subsequently transfected with HEamiRNA mimics (post-hoc Tukey’s HSD, n=10 samples 
per group, p=0.007 and p<0.0001 respectively) (Figure 11A-D). 
Furthermore, VIM expression in extravillous trophoblasts pre-transfected with 
control antagomir, and subsequently transfected with control mimic, was not 
significantly different from those transfected with HEamiRNA antagomirs and HEamiRNA 
mimics. However, VIM, SNAI1, and SNAI2 expression were significantly reduced in 
cytotrophoblasts transfected with control antagomir and HEamiRNA mimics (post-hoc 
Tukey’s HSD, n=10 samples per group, p<0.0001, Figure 11E-H). Thus, our data 
suggest that pretreating cells with HEamiRNA antagomirs prevents inhibition of EMT 
pathway members resulting from transfection with HEamiRNA mimics in 









miRNA impair extravillous trophoblast invasion  
Transwell invasion of HTR8 extravillous trophoblasts following A) 0, 60, 120, and 320mg/dL ethanol 
exposure or transfection with B) 
HEa
miRNA mimics or C) hairpin inhibitors with or without concomitant 
320 mg/dL ethanol exposure. 
O.D. = optical density, results are expressed as expressed as the mean ± SEM; n=10 samples per group; 
*p<0.05 by Unpaired T-test 
 
3.8 HEamiRNAs impair extravillous trophoblast invasion 
Functionally, inhibition of the EMT pathway should reduce trophoblast 
invasiveness. Thus, we performed a transwell invasion assay using HTR8 extravillous 
trophoblasts transfected with HEamiRNA mimics and antagomirs. While ethanol 
exposure by itself did not impair trophoblast invasion (Figure 12A), there was a 
marginally significant interaction effect between ethanol exposure and HEamiRNA mimic 
transfection (F1,28=3.418, p=0.075). Thus, a planned comparison indicated that 
transfection with HEamiRNA mimics significantly reduced trophoblast invasion in the 
context of 320 mg/dL ethanol co-exposure, relative to the control mimics (t(14)=2.762, 
p=0.015), consistent with our data demonstrating HEamiRNAs interfere with the EMT 
pathway (Figure 12B). Contrastingly, transfecting HEamiRNA antagomirs increased 
invasion in the context of 320 mg/dL ethanol co-exposure, though this effect was only 





3.9 HEamiRNAs retard trophoblast cell cycle progression 
Given the proliferative nature of cytotrophoblasts, and the intimate relationship 
between EMT and cell cycle (72, 73), we assessed the effects of ethanol and HEamiRNAs 
on BeWO cytotrophoblast cell cycle. After pulse-labeling cells with the nucleic acid 
analog, 5-Ethynyl-2'-deoxyuridine (EdU), for 1-hour, we found that individually 
transfecting 6 of the HEamiRNA mimics increased EdU incorporation (Unpaired t-test, 
p<0.05, FDR correction), suggesting an overall increased rate of DNA synthesis (Figure 
13). Consistent with the increased rates of DNA synthesis resulting from individual 
HEamiRNA mimic transfection, individual transfection of HEamiRNAs antagomirs 
generally reduced EdU incorporation, though only the antagomir to hsa-miR-760 did so 










Figure 13: Individual 
HEa
miRNAs interfere with trophoblast cell cycle dynamics 
Heatmap for degree of EdU incorporation in BeWO cytotrophoblasts following individual 
HEa
miRNA 
overexpression (top, OE) or transfection with individual 
HEa
miRNA hairpin inhibitors (bottom, HI). Scale 
for heatmap coloration, right, denotes fold change of EdU incorporation intensity relative to control mimic 
or hairpin transfection. N=6 samples per group, white asterisks denote 
HEa
miRNA mimics or hairpin 
inhibitors that had a significant effect, p<0.05, Student’s T-test, on degree of EdU incorporation. 
 
Contrastingly, simultaneous transfection of HEamiRNAs significantly reduced 
EdU incorporation (F(1,26)=59.69, p<0.0001,  Figure 14A). Interestingly, simultaneous 
administration of antagomirs also reduced EdU incorporation, as observed with the 
pooled HEamiRNAs mimics (F(1,26)=34.83, p=0.0005, Figure 14B). This reduction in EdU 









miRNAs inhibit the rate of DNA synthesis in trophoblasts 
A) Degree of EdU incorporation following control and 
HEa
miRNA overexpression.  
B) Degree of EdU incorporation following control and 
HEa
miRNA hairpin inhibitor transfection.  
C) Degree of EdU incorporation in BeWO cytotrophoblasts following 0, 60, 120, and 320mg/dL ethanol 
exposure. n=5 samples per group.  
ANOVA: significant main effect of HEamiRNA transfection [ ###p<0.001, and ####p<0.0001]. 
 
To further characterize the coordinated effect of HEamiRNAs on cytotrophoblast 
cell cycle, we pulse-labeled cells with EdU for 1-hour and, post-fixation, labelled them 
with 7-Aminoactinomycin D (7AAD) to segregate cells into three groups: G0/G1 
(7AADlow, EDU-), S (EDU+), and G2/M (7AADhigh, EDU-). Both 120 mg/dL and 320 
mg/dL ethanol exposures significantly decreased the proportion of cells in S-phase, 
while 320 mg/dL exposure increased the proportion of cells in G2/M-phase, consistent 
with the observed reduction in the rate of DNA synthesis (Figure 15A). Similar, to the 
effects of ethanol exposure, pooled HEamiRNA mimic administration also significantly 
decreased the proportion of cells in S-phase (F(1,28)=52.78, p<0.0001) while increasing 
the proportion of cells the G2/M-phase (F(1,28)=8.395, p=0.007) and exacerbated 
alcohol’s effects on the cell cycle (Figure 15B). Interestingly, pooled HEamiRNA 





p=0.0007) and increased the proportion of those in G2/M-phase (F(1,26)=12.38, p=0.002) 
(Figure 15C). 
 
Figure 15: HEamiRNA cause cell cycle retardation in trophoblasts  




, S, or G
2
/M phase of the cell cycle following 0, 60, 
120, and 320mg/dL ethanol exposure. 




, S, or G
2
/M phase of the cell cycle following 
control and 
HEa
miRNA overexpression.    




, S, or G
2
/M phase of the cell cycle following 
control and 
HEa
miRNA hairpin inhibitor transfection with or without concomitant 320 mg/dL ethanol 
exposure.  
For box and whisker plots, bounds of box demarcate limits of 1st and 3rd quartile, line in middle is the 
median, and whiskers represent the range of data. Representative flow cytometry experiment images are 
shown on the right. 
 n=10 samples per group; ANOVA: significant main effect of HEamiRNA transfection [##p<0.01, 
###p<0.001, and ####p<0.0001]; significant main effect of 320mg/dL ethanol exposure [
Ɛ
p<0.05]. For post-
hoc analysis, *p<0.05 and **p<0.01 by Tukey’s HSD. 
 
We sought to determine if pretreating cytotrophoblasts with pooled HEamiRNA 





transfecting HEamiRNA mimics. Cells transfected with the control or pooled HEamiRNA 
antagomirs, and subsequently transfected with pooled HEamiRNA mimics, did not have 
significantly different cell cycle profiles or rates of DNA synthesis to each other but had 
significantly lower rates of DNA synthesis (ANOVA, F(2,12)=16.56, p=0.0004), and a 
decreased proportion of S-phase cells (F(2,12)=11.43, p=0.002) with an increased 
proportion of cells in G2/M phase (F(2,12)=11.47, p=0.002), compared to cells transfected 
with both the control antagomir and control mimic (Figures 16A and B).  Collectively, 
our data indicate that transfection of these antagomirs prevents further reduction in the 
rate of DNA synthesis, or cell cycle retardation, that would result from transfection with 
pooled HEamiRNA mimics.  
 
Figure 16: Antagomirs prevent
 HEa
miRNA induced cell cycle retardation  
A) Degree of EdU incorporation following control or 
HEa
miRNA hairpin inhibitor transfection followed by 
control or 
HEa
miRNA overexpression in BeWO cytotrophoblasts. Results are expressed as expressed as the 
mean ± SEM. 




, S, or G
2
/M phase of the cell cycle following 
control or 
HEa
miRNA hairpin inhibitor transfection followed by control or 
HEa
miRNA overexpression in 
BeWO cytotrophoblasts. Bounds of box demarcate limits of 1st and 3rd quartile, line in middle is the 
median, and whiskers represent the range of data. Representative flow cytometry experiment images are 
shown on the right. 
In subheadings: C denotes control miRNA mimic or hairpin whereas T denotes 
HEa
miRNA mimic or 
hairpin inhibitor. n=5 samples per group; ANOVA: significant treatment effect [###p<0.001]. For post-hoc 







3.10 HEamiRNAs have minimal effect on cell survival 
We next sought to investigate whether ethanol- and HEamiRNA-induced changes 
in cell cycle were related to an increase in cell death. Only the 320 mg/dL dose of 
ethanol exposure demonstrated a slight, but marginally significant effect, of increasing 
lytic cell death (t(18)=2.022, p=0.054), though there was no effect on apoptosis (Figures 
17A and B). However, the changes in cell cycle following transfection of individual or 
pooled HEamiRNA mimics were not mirrored by changes in lytic cell death. 
Nevertheless, two HEamiRNAs, hsa-mir-671-5p and hsa-mir-449a, did significantly 
increase apoptosis (Unpaired t-test, p<0.05, FDR correction) (17C and D).  
Contrastingly, transfection of 4 HEamiRNA antagomirs individually, significantly 
increased lytic cell death (Unpaired t-test, all p<0.05, FDR correction), with the 
antagomir to hsa-mir-491-3p also increasing apoptotic cell death (t(14)=3.383, p=0.004, 
FDR correction, Figure 17C and D). Likewise, transfection of pooled HEamiRNA 
antagomirs increased lytic cell death (F(1,36)=11.40, p=0.002) but did not cause increased 
apoptosis, whereas HEamiRNA had minimal effects on lytic or apoptotic cell death 
(Figures 18A-D). Taken together, our data suggest that while ethanol exposure may 
increase cytotrophoblast death, increased levels of HEamiRNAs have minimal effects on 
cell death, suggesting that their effect on cell cycle and the EMT pathway is independent 







Figure 17:  The effect of ethanol and individual 
HEa
miRNAs on lytic and apoptotic cell death 
A) Quantification of lytic cell death in BeWO cytotrophoblasts following 0, 60, 120, and 320mg/dL 
ethanol exposure (n=10 samples per group). 
B) Quantification of apoptotic cell death in BeWO cytotrophoblasts following 0, 60, 120, and 320mg/dL 
ethanol exposure (n=8 samples per group). 
C) Heatmap of lytic cell death in BeWO cytotrophoblasts following individual 
HEa
miRNA overexpression 
(top, OE) or transfection with individual 
HEa
miRNA hairpin inhibitors (bottom, HI). Scale for heatmap 
coloration, bottom, denotes fold change of lytic cell death relative to control mimic or hairpin transfection. 
N=10 samples per group, white asterisks denote 
HEa
miRNA mimics or hairpin inhibitors that had a 
significant effect, p<0.05, Student’s t-test, on lytic cell death. 
D) Heatmap of apoptotic cell death in BeWO cytotrophoblasts following individual 
HEa
miRNA 
overexpression (top, OE) or transfection with individual 
HEa
miRNA hairpin inhibitors (bottom, HI). Scale 
for heatmap coloration, bottom, denotes fold change of apoptotic cell death relative to control mimic or 
hairpin transfection. N=10 samples per group, white asterisks denote 
HEa
miRNA mimics or hairpin 







Figure 18:  
HEa
miRNAs influence lytic and apoptotic cell death 
A) Quantification of lytic cell death in BeWO cytotrophoblasts following 
HEa
miRNAs or control miRNA 
overexpression with or without concomitant 320mg/dL ethanol exposure (n=10 samples per group). 
B) Quantification of lytic cell death in BeWO cytotrophoblasts following transfection with 
HEa
miRNA or 
control hairpin inhibitors with or without concomitant 320mg/dL ethanol exposure (n=10 samples per 
group). 
C) Quantification of apoptotic cell death in BeWO cytotrophoblasts following 
HEa
miRNA mimics or 
control miRNA overexpression with or without concomitant 320mg/dL ethanol exposure (n=10 samples 
per group). 
D) Quantification of apoptotic cell death in BeWO cytotrophoblasts following transfection with 
HEa
miRNA or control hairpin inhibitors with or without concomitant 320mg/dL ethanol exposure (n=10 
samples per group). 
Results are expressed as expressed as the mean ± SEM; ANOVA: significant main effect of 320mg/dL 
ethanol exposure [
ƐƐƐ






3.11 HEamiRNAs modulate cytotrophoblast differentiation-associated Ca2+ dynamics 
HEamiRNAs’ effects on EMT pathway member expression, coupled with cell 
cycle retardation, indicates that HEamiRNAs influence trophoblast maturation. 
Maturation of cytotrophoblasts into syncytiotrophoblasts is marked by dramatic changes 





producing syncytiotrophoblasts, we used a well-established protocol of forskolin 
induced syncytialization of BeWO cytotrophoblasts  (75, 76). As expected, forskolin 
treatment induced fusion/syncytialization of cytotrophoblasts resulting in a greater 
average cell size in the forskolin + HEamiRNA mimics group (F(1,386)=4.386, p=0.037). 
This suggests that the inhibition of EMT by these miRNAs may result in preferential 
syncytialization instead of differentiation to extravillous trophoblasts (Figure 19). 
 
Figure 19: HEamiRNAs promote syncytialization-dependent increases in cell size  
Box and whisker plot of BeWO cytotrophoblast size (left) following 
HEa
miRNA overexpression with or 





quartile, line in middle is the median, and whiskers represent the range of data; ANOVA: significant 
interaction effect (sex by PAE, [
†
p<0.05]). For post-hoc analysis, *p<0.05 and ***p<0.001 by Tukey’s 
HSD. 
 
Ethanol and forskolin treatment both increased baseline calcium levels, as 
indicated by the change in fluo-4 fluorescence (F(1,426)=5.593 and 3.665 respectively, 
p<0.0001, Figures 20A-D). The effect of ethanol on baseline calcium was abrogated by 
HEamiRNAs while HEamiRNAs + forskolin was not significantly different to forskolin 
alone, indicating that forskolin and HEamiRNAs may be affecting similar calcium 
pathways. Syncytiotrophoblasts actively transport high amounts of calcium from 





basal transport of calcium into the cells due to increased expression of plasma membrane 
channels (77). The conversion of trophoblasts to syncytiotrophoblasts is accompanied by 
an increase in endoplasmic reticulum, which could increase calcium buffering 
capabilities in response to ethanol-stress on the cells, thus HEamiRNA-induced 
syncytialization pathways may be protective against ethanol stress. 
Adaptations to cellular stress can be seen in alterations to cellular energetics in 
response to ethanol, as ethanol-exposed BeWO cells showed decreased baseline and 
stressed oxygen consumption rates (OCR) (F(1,28)=15.55 and 16.91, p=0.0005 and 0.0003 
respectively) and increased extracellular acidification rates (ECAR) (F(1,28)=4.868, 










miRNAs influence differentiation associated Ca
2+ 
dynamics 
A) Time-lapse confocal images of BeWO cytotrophoblasts loaded with fluo-4 Ca
2+
 indicator dye under 
indicated treatment conditions. Arrowhead indicates a fused, multinuclear cell, scale bar is 50µm. 
B) Box and whisker plot baseline intracellular calcium levels in BeWO cytotrophoblasts with control and 
HEa
miRNA overexpression with or without concomitant 320mg/dL ethanol exposure (n=69 to 154 samples 
per group). 
C) Box and whisker plot of baseline intracellular calcium levels in BeWO cytotrophoblasts with control 
and 
HEa
miRNA overexpression with or without 20μm forskolin treatment (n=51 to 136 samples per group). 
D) Trace of Intracellular Calcium Levels at baseline and following administration of the indicated 
compounds, as well as schematic and equations used to calculate relative fluorescence intensities (n=51-
136 cells per group). 




 quartile, line in middle is the 














miRNAs have minimal effects on trophoblast metabolism 
A) Baseline oxygen consumption rate (OCR), B) baseline extracellular acidification rate (ECAR), C) 
stressed OCR, and D) stressed ECAR in BeWO cytotrophoblasts with control and 
HEa
miRNA 
overexpression with or without concomitant 320mg/dL ethanol exposure. Metabolic stress was induced by 
treatment with 1μm Oligomycin and 0.125µM (FCCP). Results are expressed as expressed as the mean ± 
SEM. 
n=10 samples per group; ANOVA: significant main effect of 320mg/dL ethanol exposure [Ɛp<0.05, 
ƐƐƐp<0.001], significant interaction effect (HEamiRNA by 320mg/dL ethanol, [†p<0.05]). For post-hoc 
analysis, **p<0.01, ***p<0.001, and ***p<0.0001 by Tukey’s HSD. 
 
Extracellular adenosine triphosphate (ATP) has been shown to inhibit trophoblast 
migration (78) and can directly stimulate increased intracellular calcium elevations 
through purinergic receptors ubiquitously present on trophoblasts (79). Both HEamiRNA 
and ethanol administration significantly increased intracellular calcium in response to 
acute ATP administration (F(1,426)=10.34 and F(1,386)=16.30, p=0.001 and p<0.0001 
respectively) (Figure 22A). This may be indicative of a lack of downregulation of 
purinergic receptors required in trophoblast migration as part of the interrupted EMT 
pathway. Forskolin-induced maturation decreased calcium response to ATP 
(F(1,386)=50.72, p<0.0001) (Figure 22B) and prevented the HEamiRNA-induced increase 
in ATP response. These data agree with previous studies showing increased nuclear 





placental development, which may decrease the overall calcium influx in response to 




miRNAs influence ATP-exposure associated Ca
2+ 
dynamics 
A) Box and whisker plot of intracellular calcium levels following acute ATP administration in BeWO 
cytotrophoblasts with control and 
HEa
miRNA overexpression with or without concomitant 320 mg/dL 




 quartile, line in middle is the median, and 
whiskers represent the range of data. 
B) Box and whisker plot of intracellular calcium levels following acute ATP administration in BeWO 
cytotrophoblasts with control and 
HEa
miRNA overexpression with or without 20 μm forskolin treatment. 
n=10 samples per group; ANOVA: significant interaction effect (HEamiRNA by 320mg/dL ethanol, 
[††p<0.01, and ††††p<0.0001]). For post-hoc analysis, **p<0.01 and ***p<0.001 by Tukey’s HSD. 
 
3.12 HEamiRNAs promotes syncytialization-dependent hormone production 
Transfection of HEamiRNA mimics did not change CGA, CGB, or IGF2 transcript 
expression relative to the control in non-syncytialized trophoblasts. However, following 
syncytialization (Figure 23A), HEamiRNA mimics significantly increased expression of 
CGA and CGB (post-hoc Tukey’s HSD, n=10 samples per group, p=0.001 and 0.005 
respectively). Consistent with our previous results, HEamiRNA mimics also increased 
CDH1 expression in both cytotrophoblasts and syncytiotrophoblasts (F(1,20)=5.286, 
p=0.032); there was also a main effect of syncytialization on CDH1 expression, as has 
been previously reported (F(1,36)=3.391, p=0.034, Figures 23B-E). Likewise, HEamiRNAs 





decreased it (F(1,20)=10.24, p=0.005) (Figure 23F). On the other hand, there was no effect 
of HEamiRNA antagomirs on CGA and CGB expression, although we did observe a 
decrease in IGF2 transcript expression, following syncytialization, relative to controls 
(post-hoc Tukey’s HSD, n=10 samples per group, p=0.001) (Figure 23G-J). 
Given that HEamiRNAs promotes syncytialization-dependent hormone 
production, we next investigated maternal plasma levels of intact human chorionic 
gonadotropin (hCG) in our Ukraine birth cohort. Plasma hCG levels were non-
significantly increased in the second trimester of HEa group mothers relative to their UE 
counterparts, consistent with previous studies (81). During the third trimester, however, 
hCG levels remained significantly elevated in HEa group mothers compared to the UE 
group (Median Test, n=23 samples in HEa group and n=22 for HEua and HEa groups, 
p=0.03) (Figure 24A). Furthermore, there was no significant difference of gestational 
age at blood draw between the different groups indicating the increased level of hCG in 
the HEa group was not confounded by gestational age at which blood was sampled 
(Figure 24B) (82). Interestingly, both alcohol and hCG levels were negatively associated 
with gestational age at delivery (GAD), with a significant interaction between 
periconceptional alcohol exposure and hCG levels on GAD (Table 4). Taken together, 








Figure 23: HEamiRNAs promote syncytialization dependent hCG production 
A) Diagram of a placental anchoring villous and maternal decidua with the boxed area denoting 
syncytiotrophoblasts. 
Expression of B) CGA, C) CGB, D) IGF2, and E) CDH1 transcripts F) and densitometric quantification of 
E-cadherin protein levels in BeWO cytotrophoblasts following HEamiRNAs or control miRNA 
overexpression with or without 20 μm forskolin treatment. 
Expression of G) CGA, H) CGB, I) IGF2, and J) CDH1 transcripts K) and densitometric quantification of 
E-cadherin protein levels in BeWO cytotrophoblasts following HEamiRNAs or control hairpin inhibitor 
transfection with or without 20 μm forskolin treatment.  
Results are expressed as expressed as the mean ± SEM, LDR=Molecular Weight Ladder, n=10 samples 
per group; ANOVA: significant main effect of HEamiRNA transfection [####p<0.0001], significant 
interaction effect (HEamiRNA by 320mg/dL ethanol, [†p<0.05]). For post-hoc analysis, *p<0.05, **p<0.01 







Figure 24: PAE elevates 3rd trimester maternal hCG 
A) Box and whisker plot of 2nd and 3rd trimester maternal hCG levels in UE, HEua, and HEa group 
mothers of our Ukrainian birth cohort. Bounds of box demarcate limits of 1st and 3rd quartile, line in 
middle is the median, and whiskers represent the range of data.  
B) Gestational age at third-trimester maternal blood collection across the UE, HEua, and HEa groups 
within our Ukrainian birth cohort n=22-23 samples per group; *p=0.03 (Mood’s Median Test, 2=7.043, 
df=2).  
 
3.13 HEamiRNAs reduce fetal growth 
To investigate the functional consequences of elevated circulating HEamiRNA 
levels, we administered miRNA mimics for the 8-mouse homologue HEamiRNAs, or a 
negative control mimic, through tail-vein injection to pregnant mouse dams on GD10. 
On GD18, growth parameters of male and female fetuses were assessed separately 
(Figure 25A), and data from all same-sex fetuses from a single pregnancy were averaged 
into one data point. Dams administered HEamiRNA mimics produced smaller fetuses than 
those administered control mimics, according to all collected measures of fetal size: fetal 
weight (F(1,17)=9.92, p=0.006), crown-rump length (F(1,17)=9.89, p=0.006), snout-
occipital distance (F(1,17)=9.09, p=0.008), and biparietal diameter (F(1,17)=5.99, p=0.026) 
(Figure 25B-E). Interestingly, placental weights were also significantly reduced in mice 








miRNAs restrict fetal growth 
A) Schematic for measures of crown rump length (CRL), biparietal diameter (BPD), and snout-occipital 
distance (SOD).  
B) Fetal weight, C) crown-rump length, D) biparietal diameter, E) snout-occipital distance, F) and 
placental weight at GD18 following administration of control (Ctrl) and HEamiRNA mimics to pregnant 
C57/Bl6 dams on GD10. Dots represent median measures of fetal size and placental weights from male 
and female offspring in independent litters. There were no significant differences in litter sizes [Ctrl: 8.2 
and HEamiRNAs: 8.5] or sex ratios [Ctrl: 0.86 and HEamiRNAs: 1.21] between treatment conditions (p>0.5 
for all measures). 
Results are expressed as expressed as the mean ± SEM, n=5-6 separate litters per treatment condition; 
ANOVA: significant main effect of HEamiRNA administration [#p<0.05 and ##p<0.01]. 
 
Following tail-vein administration of two human-specific sentinel miRNAs, miR-
518f-3p and miR-519a-3p, we found a high biodistribution of both miRNAs in the 
placenta, comparable to levels seen in the liver and spleen (Figure 26A and B). Thus, to 
determine whether HEamiRNA’s effects on fetal growth could result from their actions on 
the placenta, we quantified the placental expression of core EMT members in the GD18 





reduced expression of mesenchymal-associated transcript VIM (F(1,14)=14.23, p=0.002) 
and SNAI2 (F(1,14)=5.99, p=0.028) with a significant sex by HEamiRNA interaction effect 
on SNAI1 (F(1,66)=5.55, p=0.034) and CDH1 (F(1,14)=6.01, p=0.028) (Figures 27A-E). 
Interestingly, and in line with our in vitro findings whereby HEamiRNAs promoted 
syncytialization dependent cell fusion and hCG production, HEamiRNA administration 
significantly increased expression of the mRNA transcript for SynB, a gene that is 
important for syncytiotrophoblast maturation (F(1,66)=4.11, p=0.047) (Figure 27F). 
 
Figure 26: Biodistribution of miRNAs following systemic administration  
Expression of A) miR-518f-3p or B) miR-519a-3p in the indicated fetal and maternal compartments at 
GD12 following tail vein injection of control (NC) and miR-518f-3p or miR-519a-3p mimics (P) to 
pregnant C57/Bl6 dams on GD10.  








miRNAs interfere with EMT in the placenta 
Expression of A) CDH1 B) VIM C) TWIST D) SNAI1 and E) Snai2 and F) SynB transcripts in GD18 
placenta following administration of control (Ctrl) and HEamiRNA mimics to pregnant C57/Bl6 dams on 
GD10. 
Dots represent median expression values of male and female offspring in independent litters. Results are 
expressed as expressed as the mean ± SEM, n=5-6 separate litters per treatment condition, ANOVA: 
significant main effect of HEamiRNA administration [#p<0.05, ###p<0.001], significant interaction effect 
(fetal sex by HEamiRNA administration, [†p<0.05]). For post-hoc analysis, *p<0.05 by Tukey’s HSD. 
 
3.14 HEamiRNAs reduce placental-directed blood flow 
Given the profound effects of HEamiRNA administration on inhibiting fetal and 
placental growth as well as placental EMT, we next decided to characterize their effects 
on blood-flow dynamics at the maternal-fetal interface (Figure 28). Interestingly, we 
found that fetuses of HEamiRNA treated dams had a non-significantly reduced pulsatile 
acceleration in the uterine arteries compared to those from control treated dams at GD18 
(Figure 29A). Furthermore, HEamiRNA treatment also produced marginally significantly 





test, p=0.089 and 0.092 respectively), and a significantly reduced blood flow velocity 
time integral (Unpaired t-test, 0=0.031) (Figures 29B-D). There was also a non-
significant trend towards reduced pulsatile acceleration in the ascending aorta (Unpaired 
t-test, p=0.032) while there was no effect on flow velocities within the ascending aorta 










Figure 28: Tracing of fetal blood flow dynamics 
Ultrasound measurement of blood flow velocity and acceleration on ascending aorta of GD12 fetus. Red 
arrow demarcates blood flow acceleration measured from beginning of reading to peak. Green arrow 
demarcates blood flow velocity measured by tracing the parameter of measurement curve. Imaging and 
measurements of blood-flow dynamics were taken repeatedly for each pregnant dam on GD12, GD14 and 
GD18 for both the umbilical and ascending arteries for a fetus in the upper left and upper right quadrant of 






Figure 29: Effects of HEamiRNAs on mouse model umbilical and fetal blood flow dynamics 
A) Pulsatile acceleration, B) mean blood flow velocity, C) Peak blood flow velocity, and D) Velocity 
Time Integral in the fetal ascending aorta. 
E) Pulsatile acceleration, F) mean blood flow velocity, G) Peak blood flow velocity, and H) Velocity Time 
Integral in the umbilical aorta.  







Table 1: List of primer sequences used 









































































































































































































































































Table 2: HEamiRNAs are significantly correlated with independent measures of infant size 
The correlation of 2nd and 3rd trimester maternal plasma HEamiRNA levels with independent measures of 
infant size. HEamiRNAs and their significantly correlated sex and gestational age-adjusted growth 
parameters appear in bold. *p<0.05, **p<0.01.   
 
   Weight   Height  Head Circumference 
MIMAT # Trimester Sig. R2 ρ Sig. R2 ρ Sig. R2 ρ 
MIMAT0004569 2 0.821 1.224 -0.051 0.066 9.572 -0.179 0.8 1.732 -0.104 
MIMAT0004561 2 0.462 6.347 0.068 0.17 12.607 -0.074 0.134 10.903 0.103 
MIMAT0000687 2 0.552 1.113 0.029 0.069 9.299 -0.203 0.036* 8.65 0.1 
MIMAT0004765 2 0.172 3.61 0.112 0.849 2.033 -0.055 0.024* 12.529 0.156 
MIMAT0004948 2 0.142 4.227 -0.174 0.044* 7.667 -0.231 0.59 1.36 -0.115 
MIMAT0002842 2 0.246 2.517 0.134 0.918 2.134 -0.118 0.007** 14.561 0.219 
MIMAT0004957 2 0.059 6.314 0.195 0.22 4.096 0.079 0.055 10.158 0.195 
MIMAT0003880 2 0.123 7.24 0.11 0.578 5.264 -0.031 0.073 10.794 0.107 
MIMAT0001541 2 0.101 11.584 0.104 0.718 5.851 -0.072 0.173 10.036 0.068 
MIMAT0000265 2 0.026* 12.377 0.184 0.272 4.973 0 0.131 7.095 0.108 
MIMAT0002869 2 0.034* 7.975 0.153 0.403 6.83 -0.012 0.093 8.181 0.096 
MIMAT0004569 3 0.875 0.993 -0.046 0.018* 10.709 -0.196 0.577 4.696 -0.01 
MIMAT0004561 3 0.538 2.055 0.049 0.37 2.029 -0.109 0.784 3.697 0.002 
MIMAT0000687 3 0.511 0.762 0.005 0.514 1.769 -0.072 0.87 3.786 -0.077 
MIMAT0004765 3 0.824 3.165 -0.028 0.2 12.122 -0.121 0.747 4.188 -0.081 
MIMAT0004948 3 0.807 0.148 0.029 0.102 4.686 -0.156 0.376 5.009 0.032 
MIMAT0002842 3 0.515 2.099 0.109 0.421 1.715 0.016 0.245 7.917 0.152 
MIMAT0004957 3 0.368 1.396 0.141 0.761 0.716 -0.022 0.207 6.052 0.172 
MIMAT0003880 3 0.055 8.715 0.155 0.367 3.521 -0.133 0.076 8.196 0.15 
MIMAT0001541 3 0.995 0.085 -0.06 0.982 0.678 -0.151 0.026* 12.022 0.135 
MIMAT0000265 3 0.019* 11.872 0.23 0.206 5.589 0.022 0.002** 18.683 0.319 




miRNAs collectively explain the variance in independent measures of infant size 
R
2







levels fit onto sex and gestational-age adjusted growth parameters.  
 
  2nd Trimester R2 3rd Trimester R2 
Weight 24.983 13.303 
Height 24.568 13.505 







Table 4: Maternal alcohol consumption and hCG levels are negatively correlated with gestational 
age at delivery 
 
  Estimate C.I. Sig. 
AAD0       
(Intercept) 39.37 (31.41, 47.33) <.001*** 
AAD0 -8.71 (-15.98, -1.43) 0.020* 
hCG Level (log) -0.87 (-1.7, -0.03) 0.042* 
Gestational Age at Blood Draw 0.18 (0.02, 0.33) 0.028* 
AAD0:hCG Level (Interaction) 1.2 (0.05, 2.35) 0.040* 
AADD0       
(Intercept) 38.42 (30.55, 46.28) <.001*** 
AAD0 -2.65 (-6.3, 1.01) 0.153 
hCG Level (log) -0.7 (-1.63, 0.23) 0.137 
Gestational Age at Blood Draw 0.17 (0.02, 0.33) 0.028* 
AADD0:hCG Level 
(Interaction) 0.36 (-0.22, 0.94) 0.222 
AADXP       
(Intercept) 38.22 (32.01, 44.44) <.001*** 
AADXP -31.84 (-69.34, 5.67) 0.095 
hCG Level (log) -0.57 (-1.13, 0) 0.049* 
Gestational Age at Blood Draw 0.15 (0, 0.3) 0.052 
AADXP:hCG Level 
(Interaction) 4.54 (-1.86, 10.93) 0.161 
AADDXP       
(Intercept) 37.96 (31.85, 44.07) <.001*** 
AADDXP -2.67 (-10.08, 4.73) 0.473 
hCG Level (log) -0.49 (-1.05, 0.07) 0.085 
Gestational Age at Blood Draw 0.15 (0, 0.3) 0.051 
AADDXP:hCG Level 








In a prior study, we reported that gestational elevation of 11 maternal plasma 
miRNAs, in a Ukrainian clinical cohort, predicted which PAE infants would exhibit 
adverse outcomes at birth (11). These HEamiRNAs were elevated throughout mid and 
late-pregnancy, encompassing critical periods for fetal development, and were predicted 
to target key developmental pathways (11). Given that HEamiRNAs are placentally 
enriched and their dysregulation is associated with placental-associated gestational 
pathologies, we sought to determine if they also contributed to the pathophysiology of 
FASDs.  
To mimic the alcohol consumption patterns in our Ukrainian cohort, we adopted 
moderate alcohol self-administration paradigms during mouse and macaque gestation. 
Though these species share a hemochorial placenta, fundamental differences in placental 
anatomy remain. Specifically, macaque trophoblasts exhibit deeper invasion into the 
uterine horn than their mouse counterparts (83-86). Despite these differences, we found 
PAE inhibited mesenchymal transition-associated mRNA transcripts in both our models, 
indicating a conserved effect of PAE on placental development.  Additionally, we found 
that HEamiRNAs mediated the effects of PAE on core EMT pathway members in the 
placenta, and collectively though not individually, inhibited EMT in human 
cytotrophoblast and extravillous trophoblast culture models. The components of the 
EMT pathway were selected for assessment based on a substantial literature that 
 
* Part of this chapter is reprinted with permission from “Maternal circulating miRNAs that predict infant 
FASD outcomes influence placental maturation” by Tseng et al., 2019. Life Science Alliance, Vol. 2, © 





implicates these as core EMT components  (13, 17, 18, 67-70). However, analysis of 
their 3’UTRs indicates that these are unlikely to be the direct targets of HEamiRNA 
action. Additional studies will be needed to dissect out the signaling networks that 
connect HEamiRNAs to the assessed EMT components.  
Interestingly, HEamiRNAs also promoted syncytialization (forskolin)-dependent 
hCG expression, mirroring the elevation of third trimester maternal hCG levels in the 
PAE group within our Ukrainian birth cohort. This late-gestation elevation of hCG levels 
may serve as a compensatory mechanism to prevent the preterm birth associated with 
PAE, as hCG during late gestation is hypothesized to promote uterine myometrial 
quiescence (87, 88). In support of this hypothesis, we found significant negative 
associations between both hCG levels and alcohol consumption with gestational age at 
delivery. Furthermore, there was a significant interaction between periconceptional 
alcohol exposure and hCG levels, with higher hCG levels corresponding to a smaller 
effect of alcohol exposure at conception on gestational age at delivery, indicating that 
hCG moderates the effect of alcohol on age at delivery (Table 4). 
Since HEamiRNAs collectively prevented trophoblast EMT, we hypothesized that, 
as a functional consequence, these maternal miRNAs would also inhibit fetal growth. 
When we delivered 8 out of the 11 HEamiRNAs known to be present in mouse, to 
pregnant dams during the period of placental branching morphogenesis and endometrial 
invasion, when EMT is particularly active, we found that HEamiRNAs reduced fetal 
growth. Importantly, ethanol exposure during this period has also been shown to result in 





maternal miRNA-mediated deficits in trophoblast invasion may mediate some of the 
effects of PAE on fetal growth. In support of this, we found placentas from the 
HEamiRNA treated group had impaired expression of core EMT pathway members. It is 
also feasible that HEamiRNAs disrupt fetal growth through placental vascular dynamics. 
Indeed, we observed reduced placentally-directed blood flow in the HEamiRNA-treated 
group compared to controls. Furthermore, the non-human primate tissue analyzed here 
was derived from animals that were characterized in vivo using MRI and ultrasound 
imaging, which demonstrated that maternal blood supply to the placenta was lower in 
ethanol-exposed animals compared to controls, and that oxygen availability to the fetal 
vasculature was reduced (91). Thus, one possibility is that compromised trophoblast 
invasion contributes to impaired maternal blood flow in ethanol-exposed individuals, as 
we have also previously observed in mouse models (92).  
Impaired nutrient uptake in the placenta, such as dysfunction in the amino acid, 
glucose, and fatty acid transport systems have also been implicated in gestational 
pathologies, such as intrauterine growth restriction (93). Furthermore, in vitro studies in 
trophoblasts have shown alcohol exposure selectively impairs a subset of these amino 
acid and fatty acid transport systems (94, 95) whilst in vivo, PAE in rodents alters 
expression of glucose transporters in the late gestation placenta (23). These placental 
dysfunctions could also have insidious effects on development that are not immediately 
detectable at birth. As an example, perturbations in placental iron transport by PAE may 
impair central nervous system development during the neonatal period, leading to 





warranted to determine if HEamiRNAs contribute to this alcohol induced impairment in 
trans-placental nutrient transport, and ultimately whether this impairment of nutrient 
transport represents another avenue through which PAE disrupts fetal development. 
It is likely that HEamiRNAs may mediate other pregnancy associated pathologies, 
aside from PAE. We identified numerous studies that reported increased circulating and 
placental levels of at least 8 out of 11 HEamiRNAs in gestational pathologies arising from 
placental dysfunction. For example, elevated levels of one HEamiRNA, miR-519a-3p, a 
member of the placentally-expressed C19MC family cluster, was reported in placentae 
of patients with pre-eclampsia, recurrent spontaneous abortion, and intrauterine growth 
restriction (40, 41, 54, 55). Interestingly, collective overexpression of the 59 C19MC 
miRNAs inhibits trophoblast migration, explaining their enrichment in the non-
migratory villous trophoblasts and suggests their downregulation is necessary for 
maturation into invasive extravillous trophoblasts (98). Thus, a greater understanding of 
the placental roles of HEamiRNAs may also help disentangle the etiology of other 
pregnancy complications. 
While our data suggest that the placenta is an important contributory source for 
circulating HEamiRNAs, the effects of HEamiRNAs likely extend beyond the placenta into 
other maternal tissues. Outside of the placenta, HEamiRNAs may circulate in association 
with lipoprotein complexes, or be encapsulated in extracellular vesicles (EVs) whose 
abundance dramatically increases during pregnancy (99, 100). Recent work has 
demonstrated that placental-derived EVs can regulate the maternal immune system as 





Interestingly, other studies also have identified endothelial cells as ready recipients for 
placental-derived EVs, suggesting placental-EVs and their cargo miRNAs participate in 
synchronizing the growth of the placenta with the accompanying maternal and fetal 
vascular remodeling (99, 105). While further investigation is warranted into the role of 
EVs and miRNAs in maternal-fetal communication, and to the extent they serve as 
paracrine/endocrine mediators for the placenta during development, targeting 
HEamiRNAs will likely have profound effects for both fetal and placental development in 
the context of FASDs and other gestational pathologies. 
While we did not investigate the effects of PAE on EMT in non-placental organs, 
it is likely that PAE broadly disrupts EMT in multiple fetal compartments. 
Developmental ethanol exposure has been shown inhibit the EMT-dependent migration 
of neural crest progenitors involved in craniofacial development, explaining the facial 
dysmorphology seen in FAS and FASDs (106, 107). Outside of its effects on the neural 
crest, PAE is significantly associated with various congenital heart defects, including 
both septal defects and valvular malformations (108-111). Septation of the heart, 
primarily atrial septation, is an EMT-dependent process, with endocardial cells 
delaminating and transdifferentiating into mesenchymal cells that populate the 
endocardial cushions as well as the muscular cap, which functions as the growing edge 
of the muscular atrial septum(112, 113). The mesenchymal cells from the endocardial 
cushions also form the cardiac valve progenitors. Thus, disruption of endocardial EMT 





Collectively, our data on HEamiRNAs suggest miRNA-based interventions could 
minimize or reverse developmental effects of PAE and other placental-related 
pathologies. miRNA-based therapeutic approaches have been advanced for other disease 
conditions. For example, Miraversentm, an anti-miR-122 antisense oligonucleotide, has 
been shown to be effective in reducing hepatitis-C viral burden (114). Additionally, a 
recent phase-1 clinical trial report indicated that liposomal delivery of a tumor-
suppressor miRNA was well tolerated in human populations and showed evidence of 
therapeutic efficacy (115). However, we also observed with HEamiRNAs that the effects 
of combinations of miRNAs are not a sum of their individual effects. Functional synergy 
between clusters of co-regulated miRNAs may be a common feature in development and 
disease. For instance, in 2007, we presented early evidence that ethanol exposure 
reduced miR-335, -21, and -153 in neural progenitors and that coordinate reduction in 
these miRNAs yielded net resistance to apoptosis following ethanol exposure (116). In 
that study, we also showed that coordinate knockdown of these three miRNAs was 
required to induce mRNA for Jagged-1, a ligand for the Notch cell signaling pathway, an 
outcome that was not recapitulated by knocking down each miRNA individually (116). 
More recently, combined administration of miR-21 and miR-146a has been 
shown to be more effective in preserving cardiac function following myocardial 
infarction than administration of either of these miRNAs alone (117). While miRNA 
synergy has not been explored in detail, these data show that new biology may emerge 
with admixtures of miRNAs, and that therapeutic interventions may require the use of 





clinical studies to date. Our study was restricted to exploring the effects of the 11 
HEamiRNAs on development, which represent only the significantly increased fraction of 
miRNAs elevated in the HEa group maternal plasma within our Ukrainian cohort. 
Indeed, the next 5 most elevated miRNAs are also abundantly expressed in the placenta 







 In conclusion, we have observed how a set of 11 miRNAs, predictive of adverse 
infant outcomes following PAE, collectively mediate the effects of alcohol on the 
placenta. Specifically, elevated levels of these miRNAs promote an aberrant 
maturational phenotype in trophoblasts by inhibiting core members of the EMT pathway 
and promoting syncytialization-dependent hormone production. Functionally, these 
miRNAs are clinically correlated with measures of fetal development and directly cause 
intrauterine growth restriction when administered in vivo. Our work suggests that a 
greater understanding for the role of HEamiRNAs during development, and their role in 
coordinating the EMT pathway in the placenta and other developing tissues, will benefit 
the understanding of FASDs and other gestational pathologies and potentially lead to 




* Part of this chapter is reprinted with permission from “Maternal circulating miRNAs that predict infant 
FASD outcomes influence placental maturation” by Tseng et al., 2019. Life Science Alliance, Vol. 2, © 
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